Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

Agora Data Achieves Industry First: Auto Loans Become Public, On-Chain Assets

View original at globenewswire.com
Agora Data Achieves Industry First: Auto Loans Become Public, On-Chain Assets ARLINGTON, Texas, March 26, 2026 (GLOBE NEWSWIRE) -- Agora Data, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Consumer auto loans can now exist as real-time, investable, blockchain-based real-world assets (RWAs), openly accessible to qualified market participants for the first time

    60% confidence

  • This achievement represents a structural transformation in auto finance. Auto loans are no longer confined to closed balance sheets traditionally held and managed inside financial institutions. Bringing them on-chain enables transparency, intelligence, and broader participation—while supporting smarter, more profitable consumer loan originations.

    60% confidence

  • Agora Data has consistently pushed the boundaries of innovation—launching the industry's first asset-pooled non-prime auto securitization in 2020 and the first to bring U.S. auto loans on-chain as tokenized real-world assets

    60% confidence

  • Public availability is a defining characteristic for blockchain-based capital markets. Agora's underwriting rigor, data discipline, and independent asset review capabilities support investor confidence. Auto loans are a compelling expansion of blockchain-enabled structured finance, grounded in real-world performance.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com